Why the smartest health service boards treat infection prevention as an investment with a measurable return, not an overhead to be trimmed. When budgets tighten, infection prevention and control (IPC) is an easy target.
It shows up on the ledger as cost: specialist staff, audits, education, personal protective equipment, and cleaning contracts. None of it bills a patient. So it gets questioned, deferred, or quietly pared back. The evidence points the other way. IPC is one of the highest-return investments a health service can make, and the return is measurable in the language a board uses: bed utilisation, patient throughput, workforce cost, funding and reputation. Organisations that treat infection prevention as a value driver, rather than a compliance overhead, protect both their patients and their margin. This is the business case.
Start with what infections actually cost you
Healthcare-associated infections are the most common complication affecting patients in Australian hospitals. Around 165,000 to 170,000 occur each year in public hospitals, and most are considered potentially preventable. They are not a rare misfortune. They are a recurring, largely avoidable cost. The scale is significant. HAIs consume an estimated two million hospital bed days in Australia every year. Surgical site infections alone account for roughly 16,541 cases annually in public hospitals, at a direct cost of about A$323.5 million, or close to A$18,814 per case. Looked at more broadly, hospital-acquired complications, which include infections, were estimated to cost the public system A$4.1 billion, or 8.9 per cent of total hospital expenditure, in a single financial year. Infection is the most prevalent of the sixteen high-priority complications monitored nationally, accounting for around 55 per cent of all hospital-acquired complications, ahead of delirium, cardiac and respiratory complications. Read those numbers as a chief financial officer would. Every avoidable infection is a bed you cannot use for funded activity, a theatre slot displaced, a longer stay you largely fund yourself, and a patient outcome that carries clinical, legal and reputational risk. The cost of infection is already in your budget. The only question is whether you are paying to prevent it or paying to treat it.
The four levers where IPC shows up on the P&L
Fewer complications, lower treatment cost
Prevention is simply cheaper than treatment. The evidence suggests that a large share of device-related infections are preventable, with studies indicating that 65 to 70 per cent of catheter-associated bloodstream and urinary tract infections can be avoided with evidence-based strategies. International economic reviews, including OECD analysis, commonly report a return of up to seven dollars for every dollar invested in infection prevention, with most studies landing between three and seven to one. Few capital projects a health service considers offer that ratio.
Shorter stays, more capacity
Bed days are the scarcest resource in most health services, and infections consume them at scale. Every infection avoided is length of stay returned to the system: capacity that can be redirected to funded activity, elective throughput and reduced access pressure. In a capacity-constrained environment, this opportunity-cost argument is often more powerful than the direct cost saving alone.
Lower agency and overtime spend
This lever is consistently underestimated. Infection outbreaks and surges drive furloughed staff, urgent backfill, and reliance on premium-rate agency and overtime cover. A stable, well-run IPC system reduces the frequency and severity of those shocks, and with them the unplanned workforce costs that blow out budgets without warning. Prevention protects the roster as much as it protects the patient.
Funding and reputation
Safety is now coded into how hospitals are paid. Since July 2018, IHACPA’s national funding model has reduced payment for admitted acute episodes in which a hospital-acquired complication occurs, and sentinel events have attracted zero funding since July 2017. The direction of travel is long-standing and clear: complications carry a funding consequence, and infection sits at the top of the sixteen high-priority complications the system monitors. Alongside funding, infection rates increasingly shape reputation. Accreditation outcomes, public reporting and consumer choice all reward organisations that keep infections low, and expose those that do not.
Building the business case
The strongest IPC business cases are built in the board’s own language. If you are making the argument internally, a few moves help it land.
- Quantify your own baseline. Pull your organisation’s HAI and HAC rates, your average length of stay and cost per case, and, crucially, your outbreak-driven agency and overtime spend over the past two years. Generic national figures open the conversation. Your own numbers win it.
- Model the avoidable share. Apply the preventability evidence to your baseline to estimate how many infections, bed days and dollars are genuinely in play. A conservative estimate you can defend is more persuasive than an ambitious one you cannot.
- Frame IPC as capacity and margin, not compliance. Translate prevented infections into freed bed days, recovered throughput, reduced workforce cost and lowered risk exposure. Present the investment against the cost of doing nothing, which is rarely zero.
- Measure and report the return. Track the same metrics after you invest, so the value is visible and the case for continued funding renews itself. An IPC program that can show its return is far harder to cut.
The part of the return that depends on people
None of these returns are automatic. They depend on people, and this is where the business case most often quietly fails. Understaffed IPC functions cannot sustain surveillance, audit and improvement. Frontline teams who are not trained do not prevent infections consistently. And a contingent workforce that arrives without proper orientation to your IPC systems reintroduces the very risk your investment is meant to remove.
That last point matters more than most budgets acknowledge. Agency and locum staff are essential to keeping services running, but if they are not credentialled, oriented and IPC-ready on arrival, they become a gap in an otherwise sound system. The return on infection prevention is only as strong as the weakest-prepared person on the floor.
The bottom line
Infection prevention is not the line you cut when budgets tighten. It is the line that protects every other line: your bed capacity, your workforce costs, your funding and your reputation. Reframed honestly, it is not an overhead at all. It is one of the clearest value drivers a health service board will find, hiding in plain sight as a cost centre. The numbers back this up, from a seven-fold return on prevention to the two million bed days infections consume each year. At Healthcare Australia, we help organisations protect that return. We supply experienced IPC clinicians, build infection-prevention capability across permanent and contingent teams, and ensure the people we place arrive credentialled, compliant, and ready to uphold your standards from the first shift. Talk to us about your infection control workforce.
